- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT04973605
Uno studio di fase 1b/2 sul BGB-11417 in monoterapia e in varie combinazioni con desametasone e carfilzomib nel mieloma multiplo
Uno studio di fase 1b/2 di aumento della dose e di espansione della coorte per determinare la sicurezza e l'efficacia di BGB-11417 come monoterapia, in combinazione con desametasone e carfilzomib/desametasone in pazienti con mieloma multiplo recidivato/refrattario e t(11;14)
The purpose of this study is to assess the safety, tolerability, and efficacy of sonrotoclax as monotherapy and in various combinations in patients with relapsed/refractory (R/R) multiple myeloma (MM) and chromosomal translocation t(11;14).
The study investigates sonrotoclax alone and in combination with dexamethasone and other agents, including carfilzomib, daratumumab, and pomalidomide.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some of our older studies were sponsored under the name BeiGene, you may see both names used for this study on this website.
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 2
- Fase 1
Contatti e Sedi
Contatto studio
- Nome: BeOne Medicines
- Numero di telefono: 1.877.828.5568
- Email: clinicaltrials@beonemed.com
Luoghi di studio
-
-
Australian Capital Territory
-
Garran, Australian Capital Territory, Australia, ACT 2605
- Reclutamento
- Canberra Hospital
-
-
New South Wales
-
Kingswood, New South Wales, Australia, NSW 2747
- Reclutamento
- Nepean Hospital
-
-
Victoria
-
Clayton, Victoria, Australia, VIC 3168
- Reclutamento
- Monash Health
-
Fitzroy, Victoria, Australia, VIC 3065
- Reclutamento
- St Vincents Hospital Melbourne
-
Melbourne, Victoria, Australia, VIC 3004
- Reclutamento
- The Alfred Hospital
-
-
Western Australia
-
Perth, Western Australia, Australia, WA 6000
- Reclutamento
- Royal Perth Hospital
-
-
-
-
-
Brasília, Brasile, 70200-730
- Reclutamento
- Hospital Sirio Libanes Brasilia
-
Brasília, Brasile, 70390140
- Reclutamento
- Instituto Dor de Pesquisa E Ensino Distrito Federal
-
Porto Alegre, Brasile, 90110-270
- Reclutamento
- Centro Gaucho Integrado de Oncologia Hospital Mae de Deus
-
Salvador, Brasile, 41253-190
- Reclutamento
- Hospital Sao Rafael (Rede Dor)
-
São Paulo, Brasile, 05652-900
- Reclutamento
- Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
-
São Paulo, Brasile, 01401-004
- Reclutamento
- Instituto Dor de Pesquisa E Ensino Sao Paulo
-
São Paulo, Brasile, 01308-050
- Reclutamento
- Hospital Sirio Libanes
-
-
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 1Z2
- Reclutamento
- Cross Cancer Institute
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 4E6
- Reclutamento
- British Columbia Cancer Agency the Vancouver Centre
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2M9
- Reclutamento
- Princess Margaret Cancer Centre
-
-
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Cina, 100044
- Reclutamento
- Peking University Peoples Hospital
-
Beijing, Beijing Municipality, Cina, 100000
- Reclutamento
- Peking University Third Hospital
-
Beijing, Beijing Municipality, Cina, 100020
- Reclutamento
- Beijing Chao Yang Hospital
-
-
Chongqing Municipality
-
Chongqing, Chongqing Municipality, Cina, 400030
- Reclutamento
- Chongqing Cancer Hospital
-
-
Fujian
-
Fuzhou, Fujian, Cina, 350001
- Completato
- Fujian Medical University Union Hospital
-
Xiamen, Fujian, Cina, 361003
- Completato
- The First Affiliated Hospital of Xiamen University
-
-
Guangdong
-
Guangzhou, Guangdong, Cina, 510060
- Reclutamento
- Sun Yat Sen University Cancer Center
-
-
Hebei
-
Shijiazhuang, Hebei, Cina, 050000
- Completato
- The Second Hospital of Hebei Medical University
-
-
Henan
-
Zhengzhou, Henan, Cina, 450000
- Reclutamento
- Henan Cancer Hospital
-
Zhengzhou, Henan, Cina, 450052
- Attivo, non reclutante
- The First Affiliated Hospital of Zhengzhou University
-
-
Hubei
-
Wuhan, Hubei, Cina, 430022
- Reclutamento
- Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
-
-
Hunan
-
Changsha, Hunan, Cina, 410013
- Completato
- Hunan Cancer Hospital
-
-
Jiangsu
-
Nanjing, Jiangsu, Cina, 210029
- Reclutamento
- Jiangsu Province Hospital
-
-
Jiangxi
-
Nanchang, Jiangxi, Cina, 332000
- Reclutamento
- The First Affiliated Hospital of Nanchang University Branch Xianghu
-
-
Liaoning
-
Shenyang, Liaoning, Cina, 110001
- Reclutamento
- The First Hospital of China Medical University
-
-
Shandong
-
Qingdao, Shandong, Cina, 266000
- Reclutamento
- Qingdao Municipal Hospital
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Cina, 200032
- Reclutamento
- Affiliated Zhongshan Hospital of Fudan University
-
Shanghai, Shanghai Municipality, Cina, 200434
- Completato
- Shanghai Fourth Peoples Hospital Affiliated to Tongji University
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, Cina, 301617
- Reclutamento
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciencestuanbo Branch
-
Tianjin, Tianjin Municipality, Cina, 300052
- Completato
- Tianjin Medical University General Hospital
-
-
Zhejiang
-
Hangzhou, Zhejiang, Cina, 310003
- Reclutamento
- The First Affiliated Hospital, Zhejiang University School of Medicine
-
-
-
-
Seoul Teugbyeolsi
-
GangnamGu, Seoul Teugbyeolsi, Corea del Sud, 06351
- Reclutamento
- Samsung Medical Center
-
SeochoGu, Seoul Teugbyeolsi, Corea del Sud, 06591
- Reclutamento
- The Catholic University of Korea, Seoul St Marys Hospital
-
SeodaemunGu, Seoul Teugbyeolsi, Corea del Sud, 03722
- Reclutamento
- Severance Hospital Yonsei University Health System
-
Seoul, Seoul Teugbyeolsi, Corea del Sud, 03080
- Reclutamento
- Seoul National University Hospital
-
SongpaGu, Seoul Teugbyeolsi, Corea del Sud, 05505
- Reclutamento
- Asan Medical Center
-
-
-
-
-
Poitiers, Francia, 86000
- Completato
- Chu de Poitiers Site de La Mileterie
-
-
-
-
-
Aachen, Germania, 52074
- Reclutamento
- Universitaetsklinikum Aachen
-
Dresden, Germania, 01307
- Reclutamento
- Universitatsklinikum Carl Gustav Carus An Der Technischen Universitat Dresden
-
Hamburg, Germania, 20251
- Reclutamento
- Universitatsklinikum Hamburg Eppendorf
-
Würzburg, Germania, 97080
- Reclutamento
- Universitatsklinikum Wurzburg
-
-
-
-
-
Alexandroupoli, Grecia, 68100
- Reclutamento
- University Hospital of Alexandroupolis
-
Athens, Grecia, 115 28
- Reclutamento
- General Hospital of Athens Alexandra
-
-
-
-
-
Ancona, Italia, 60020
- Reclutamento
- Azienda Ospedaliera Universitaria Delle Marche
-
Bari, Italia, 70124
- Reclutamento
- Azienda Ospedaliera Policlinico Di Bari
-
Bologna, Italia, 40138
- Reclutamento
- Policlinico Sorsola Malpighi, Aou Di Bologna
-
Meldola, Italia, 47014
- Reclutamento
- Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori Irst
-
Milan, Italia, 20141
- Reclutamento
- Istituto Europeo Di Oncologia
-
-
-
-
-
Headington, Regno Unito, OX3 7LE
- Reclutamento
- Oxford University Hospitals Nhs Trust Churchill Hospital
-
London, Regno Unito, NW1 2PG
- Reclutamento
- University College Hospital
-
Sutton, Regno Unito, SM2 5PT
- Reclutamento
- Royal Marsden Nhs Foundation Royal Marsden Hospital
-
-
-
-
-
Singapore, Singapore, 119074
- Reclutamento
- National University Hospital Singapore
-
-
-
-
-
Barcelona, Spagna, 08036
- Attivo, non reclutante
- Hospital Clinic de Barcelona
-
-
-
-
Alabama
-
Birmingham, Alabama, Stati Uniti, 35294-0004
- Reclutamento
- University of Alabama At Birmingham Hospital
-
-
California
-
Duarte, California, Stati Uniti, 91010-3012
- Reclutamento
- City of Hope National Medical Center
-
Irvine, California, Stati Uniti, 92618-2377
- Reclutamento
- City of Hope Irvine Lennar
-
-
Florida
-
Miami, Florida, Stati Uniti, 33136-2107
- Reclutamento
- University of Miami
-
-
Georgia
-
Atlanta, Georgia, Stati Uniti, 30322-1013
- Reclutamento
- Emory University Winship Cancer Center
-
-
Illinois
-
Chicago, Illinois, Stati Uniti, 60637-1443
- Reclutamento
- University of Chicago Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02114
- Completato
- Massachusetts General Hospital
-
-
Missouri
-
St Louis, Missouri, Stati Uniti, 63110-1010
- Reclutamento
- Washington University School of Medicine
-
-
New Jersey
-
Hackensack, New Jersey, Stati Uniti, 07601-1915
- Reclutamento
- Hackensack University Medical Center
-
-
New York
-
New York, New York, Stati Uniti, 10065-6800
- Reclutamento
- Memorial Sloan Kettering Cancer Center Mskcc
-
-
Ohio
-
Columbus, Ohio, Stati Uniti, 43210-1240
- Reclutamento
- The James Cancer Hospital and Solove Research Institute At Ohio State University
-
-
Utah
-
Salt Lake City, Utah, Stati Uniti, 84112-5550
- Reclutamento
- Huntsman Cancer Institute
-
-
Washington
-
Seattle, Washington, Stati Uniti, 98195
- Reclutamento
- University of Washington
-
-
Wisconsin
-
Madison, Wisconsin, Stati Uniti, 53792-0001
- Reclutamento
- University of Wisconsin Carbone Cancer Center
-
Milwaukee, Wisconsin, Stati Uniti, 53226-3522
- Reclutamento
- Medical College of Wisconsin
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
-
A confirmed diagnosis of multiple myeloma (must have an M-component in serum and/or urine)
-
Measurable disease defined as:
i. M-spike ≥ 500mg/dL, or ii. Urine protein M-spike of ≥ 200 mg/day, or iii. Serum free light chains ≥ 10 mg/dL, and an abnormal κ:λ ratio
-
Participant has documented relapsed or progressive MM on or after any regimen or who are refractory to the most recent line of therapy.
i. Relapsed MM is defined as previously treated MM that progresses and requires initiation of salvage therapy but does not meet the criteria for refractory MM.
ii. Refractory MM is defined as disease that is nonresponsive (failure to achieve minimal response or development of progressive disease) while on primary or salvage therapy or progresses within 60 days of last therapy.
- In Part 1 and Part 2 Cohorts 1 and 2 participants should have relapsed or progressive disease and have had ≥ 3 prior lines of therapy including a proteasome inhibitor, an IMiD, and an anti-CD38 monoclonal antibody, and no more available approved therapies.
- Participants in Part 2 Cohorts 3, 4, and 5 should have relapsed or progressive disease and have had ≥ 1 prior line of therapy. Prior treatment with carfilzomib is allowed but the patient must not be considered carfilzomib refractory by the investigator.
- Participants in Part 2 Cohorts 6 and 7 should have relapsed or progressive disease and have had 1 to 3 prior lines of therapy and previously treated with a proteasome inhibitor and an IMiD
-
Positivity for t(11;14) translocation must be confirmed by validated fluorescence in situ hybridization (FISH) testing assay in a pre-defined laboratory
a. fresh bone marrow aspirate sample must be collected at screening and sent to central laboratory for t(11;14) FISH testing.
-
Adequate organ function defined as:
- Hemoglobin ≥ 8.0 g/dL within 7 days before first dose of study treatment, (transfusions, in accordance with institutional guidelines, are permitted)
- Platelet count ≥ 75,000/μL, within 7 days before first dose of study treatment, independent of growth factor support and transfusions
- Absolute neutrophil count (ANC) ≥ 1000/mm^3 within 7 days before first dose of study treatment
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 x upper limit of normal (ULN) and total bilirubin ≤ 2.0 x ULN N (total bilirubin must be < 3 x ULN for patients with Gilbert's syndrome)
Exclusion Criteria:
-
Participant has any of the following conditions:
- Non secretory MM (Serum free light chains < 10 mg/dL)
- Solitary plasmacytoma
- Active plasma cell leukemia (ie, either 20% of peripheral white blood cells or > 2.0 x 109/L circulating plasma cells by standard differential)
- Waldenström macroglobulinemia (WM)
- Amyloidosis.
- Polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes (POEMS) syndrome
- Chronic respiratory disease that requires continuous oxygen
-
Significant cardiovascular disease, including but not limited to:
- Myocardial infarction ≤ 6 months before screening
- Ejection fraction ≤ 50%
- Unstable angina≤ 3 months before screening
- New York Heart Association Class III or IV congestive heart failure
- History of clinically significant arrhythmias (eg, sustained ventricular tachycardia, ventricular fibrillation, or torsades de pointes)
- Heart rate-corrected QT interval > 480 milliseconds based on Fridericia's formula
- History of Mobitz II second-degree or third-degree heart block without a permanent pacemaker in place
- Uncontrolled hypertension at screening, defined as systolic blood pressure > 170 mmHg and diastolic blood pressure > 105 mmHg by ≥ 2 consecutive measurements. Prior therapy with sonrotoclax or other agents inhibiting BCL2 activity (eg, venetoclax)
-
Known infection with human immunodeficiency virus (HIV)
-
Serologic status reflecting active viral hepatitis B (HBV) or viral hepatitis C (HCV) infection as follows:
- Presence of hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb). Participants with presence of HBcAb, but absence of HBsAg, are eligible if HBV DNA is undetectable (limitation of sensitivity < 20 IU/mL) ,), and if they are willing to undergo monthly monitoring for HBV reactivation.
- Presence of HCV antibody. Participants with presence of HCV antibody are eligible if HCV RNA is undetectable (limitation of sensitivity < 15 IU/mL).
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Part 1 Dose Escalation
Dose-escalation and de-escalation to determine maximum tolerated dose (MTD) of sonrotoclax plus dexamethasone, sonrotoclax plus dexamethasone plus carfilzomib, sonrotoclax plus dexamethasone plus daratumumab, and sonrotoclax plus dexamethasone plus pomalidomide. |
Administered orally daily
Altri nomi:
Once weekly either orally or intravenously Administered intravenously weekly Administered subcutaneously weekly Administered orally daily |
|
Sperimentale: Part 2 Cohort Expansion
There will be up to 7 expansion cohorts to further evaluate the safety and efficacy of sonrotoclax monotherapy, sonrotoclax plus dexamethasone in combination with dexamethasone plus carfilzomib, and in combination with dexamethasone plus daratumumab |
Administered orally daily
Altri nomi:
Once weekly either orally or intravenously Administered intravenously weekly |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Parte 1 e 2: numero di partecipanti che segnalano uno o più eventi avversi emergenti (TEAES), eventi avversi gravi (SAE), eventi avversi che portano a interruzione e eventi avversi di interesse speciale (ASES).
Lasso di tempo: Fino a 30 giorni dopo l'ultima dose di dose di studio
|
Fino a 30 giorni dopo l'ultima dose di dose di studio
|
|
|
Part 1: Number Of Participants Experiencing Dose-limiting Toxicities (DLTs)
Lasso di tempo: Up to 28 days
|
DLTs will be based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0 and will include most grade 3 or higher events, as defined in the protocol. |
Up to 28 days
|
|
Part 2: Overall response rate (ORR) as Assessed by Investigator
Lasso di tempo: Approximately 4 years
|
Defined as the percentage of participants who achieved a stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR) per International Myeloma Working Group (IMWG) criteria |
Approximately 4 years
|
|
Part 2: Very Good Partial Response (VGPR) or Better Response Rate as Assessed by Investigator
Lasso di tempo: Upon study termination (Baseline up to first documentation of disease progression [PD] or death from any cause [approximately 4 years]
|
Defined as the percentage of participants with a documented VGPR or better (including sCR, CR, and VGPR) |
Upon study termination (Baseline up to first documentation of disease progression [PD] or death from any cause [approximately 4 years]
|
|
Part 2: Complete Response (CR) or Stringent Complete Response (sCR) as Assessed by Investigator
Lasso di tempo: Upon study termination (Baseline up to first documentation of disease progression [PD] or death from any cause [approximately 4 years])
|
defined as the percentage of participants with a documented CR or sCR |
Upon study termination (Baseline up to first documentation of disease progression [PD] or death from any cause [approximately 4 years])
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Parte 1: Area sotto la concentrazione plasmatica Time Curva 0 all'ultima concentrazione misurabile (Auclasto) dopo una singola dose di sonrotoclax
Lasso di tempo: Ciclo 1 (ogni ciclo è fino a 28 giorni)
|
Ciclo 1 (ogni ciclo è fino a 28 giorni)
|
|
|
Parte 1: concentrazione plasmatica massima osservata (CMAX) dopo una singola dose di sonrotoclax
Lasso di tempo: Ciclo 1 (ogni ciclo è fino a 28 giorni)
|
Ciclo 1 (ogni ciclo è fino a 28 giorni)
|
|
|
Parte 1: tempo per raggiungere CMAX (TMAX) dopo una singola dose di sonrotoclax
Lasso di tempo: Ciclo 1 (ogni ciclo è fino a 28 giorni)
|
Ciclo 1 (ogni ciclo è fino a 28 giorni)
|
|
|
Parte 1: allo stato stazionario: AUC Last, SS
Lasso di tempo: Ciclo 2 (ogni ciclo è fino a 28 giorni)
|
Ciclo 2 (ogni ciclo è fino a 28 giorni)
|
|
|
Parte 1: allo stato stazionario: CMAX, SS
Lasso di tempo: Ciclo 2 (ogni ciclo è fino a 28 giorni)
|
Ciclo 2 (ogni ciclo è fino a 28 giorni)
|
|
|
Parte 1: allo stato stazionario: concentrazione plasmatica di trogolo (CTROUGH) SS
Lasso di tempo: Ciclo 2 (ogni ciclo è fino a 28 giorni)
|
Ciclo 2 (ogni ciclo è fino a 28 giorni)
|
|
|
Parte 1: allo stato stazionario: tempo per raggiungere CMAX (TMAX, SS)
Lasso di tempo: Ciclo 2 (ogni ciclo è fino a 28 giorni)
|
Ciclo 2 (ogni ciclo è fino a 28 giorni)
|
|
|
Part 2: Time to response (TTR) as Assessed by Investigator
Lasso di tempo: Approximately 4 years
|
TTR is defined as the time from start of treatment (for nonrandomized cohorts) or date of randomization (for randomized cohorts to first documentation of response of Partial Response (PR) or better |
Approximately 4 years
|
|
Part 2: Duration of response (DOR) as Assessed by Investigator
Lasso di tempo: Approximately 4 years
|
DOR is defined as the time from the date of the first documented response (PR or better) after treatment initiation until the date of first documented disease progression or death due to any cause, whichever occurs first. DOR will be analyzed only for patients who have achieved an overall response of at least PR. The distribution of DOR will be summarized by the Kaplan-Meier method. |
Approximately 4 years
|
|
Part 2: Progression-free survival (PFS) as Assessed by Investigator
Lasso di tempo: Approximately 4 years
|
PFS is defined as time from start of treatment (for nonrandomized cohorts) or date of randomization (for randomized cohorts) to the first documentation of disease progression or death, whichever occurs first |
Approximately 4 years
|
|
Part 2: Overall survival (OS) as Assessed by Investigator
Lasso di tempo: Approximately 4 years
|
OS defined as the time from start of treatment (for nonrandomized cohorts) or date of randomization (for randomized cohorts to the date of death due to any cause |
Approximately 4 years
|
Collaboratori e investigatori
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Malattie vascolari
- Malattia cardiovascolare
- Neoplasie
- Malattie del sistema immunitario
- Neoplasie per tipo istologico
- Malattie ematologiche
- Malattie linfoproliferative
- Disturbi immunoproliferativi
- Neoplasie, plasmacellule
- Disturbi emostatici
- Paraproteinemie
- Disturbi delle proteine del sangue
- Disturbi emorragici
- Malattie emiche e linfatiche
- Mieloma multiplo
- Composti policiclici
- Incinta
- In gravidanza
- Steroidi
- Composti anelli fusi
- Steroidi, fluorurati
- Incintadienetrioli
- Desametasone
- carfilzomib
- pomalidomide
- daratumumab
Altri numeri di identificazione dello studio
- BGB-11417-105
- 2021-003614-39 (Numero EudraCT)
- U1111-1277-5444 (Altro identificatore: UTN Number)
- 2023-507751-30-00 (Ctis)
- CTR20231932 (Altro identificatore: ChinaDrugTrials)
- 2023 (Sovvenzione/contratto NIH degli Stati Uniti)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
BeOne shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved.
BeOne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations.
Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeOne review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.
Periodo di condivisione IPD
See plan description
Criteri di accesso alla condivisione IPD
See plan description
Tipo di informazioni di supporto alla condivisione IPD
- STUDIO_PROTOCOLLO
- LINFA
- RSI
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .